Story · Medicine & Biotech

Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer

1 outlet · first reported by Medical Xpress on

Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase I trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from The University of… (Medical Xpress)

Coverage, in order

  1. Medical Xpress indie randomized trial
    Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer

    Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase I trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from The University of…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.